Delcath Systems (NASDAQ:DCTH) & GlucoTrack (NASDAQ:GCTK) Head to Head Review

Delcath Systems (NASDAQ:DCTH) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.

Earnings & Valuation

This table compares Delcath Systems and GlucoTrack”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$37.21 million	10.53	-$47.68 million	($0.98)	-11.96
GlucoTrack	N/A	N/A	-$7.10 million	($56.60)	0.00

GlucoTrack has lower revenue, but higher earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Delcath Systems has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, GlucoTrack has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Delcath Systems and GlucoTrack, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	0	0	4	0	3.00
GlucoTrack	0	0	0	0	0.00

Delcath Systems currently has a consensus price target of $22.75, indicating a potential upside of 94.11%. Given Delcath Systems’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Delcath Systems is more favorable than GlucoTrack.

Institutional & Insider Ownership

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 17.4% of Delcath Systems shares are held by company insiders. Comparatively, 46.5% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Delcath Systems and GlucoTrack’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delcath Systems	-150.70%	-338.16%	-104.02%
GlucoTrack	N/A	-826.43%	-707.26%

Summary

Delcath Systems beats GlucoTrack on 9 of the 13 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.